Heritage Investors Management Corp Has $16.73 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Heritage Investors Management Corp raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,936 shares of the medical equipment provider’s stock after buying an additional 6,349 shares during the quarter. Heritage Investors Management Corp’s holdings in Zimmer Biomet were worth $16,725,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at $31,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $31,000. Family Firm Inc. bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $33,000. J.Safra Asset Management Corp lifted its position in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $43,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. Raymond James cut their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, September 10th. Citigroup dropped their price objective on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Truist Financial upped their price objective on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Trading Down 0.5 %

NYSE ZBH traded down $0.52 during trading hours on Tuesday, hitting $107.89. 23,710 shares of the company’s stock were exchanged, compared to its average volume of 1,484,282. The stock has a 50-day simple moving average of $106.83 and a 200 day simple moving average of $110.66. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The firm has a market cap of $21.48 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.97 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the firm posted $1.65 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.